Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial
<p><strong>Objective</strong> To investigate whether intravenous immunoglobulin (IVIG) improves neurological outcomes in children with encephalitis when administered early in the illness.</p> <p><strong>Design</strong> Phase 3b multicentre,...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023
|
| _version_ | 1797111650517516288 |
|---|---|
| author | Hill, M Iro, M Sadarangani, M Absoud, M Cantrell, L Chong, K Clark, C Easton, A Gray, V Kneen, R Lim, M Liu, X Pike, M Solomon, T Vincent, A Willis, L Yu, L-M Pollard, AJ |
| author2 | IgNiTE study team |
| author_facet | IgNiTE study team Hill, M Iro, M Sadarangani, M Absoud, M Cantrell, L Chong, K Clark, C Easton, A Gray, V Kneen, R Lim, M Liu, X Pike, M Solomon, T Vincent, A Willis, L Yu, L-M Pollard, AJ |
| author_sort | Hill, M |
| collection | OXFORD |
| description | <p><strong>Objective</strong> To investigate whether intravenous immunoglobulin (IVIG) improves neurological outcomes in children with encephalitis when administered early in the illness.</p>
<p><strong>Design</strong> Phase 3b multicentre, double-blind, randomised placebo-controlled trial.</p>
<p><strong>Setting</strong> Twenty-one hospitals in the UK.</p>
<p><strong>Participants</strong> Children aged 6 months to 16 years with a diagnosis of acute or subacute encephalitis, with a planned sample size of 308.</p>
<p><strong>Intervention</strong> Two doses (1 g/kg/dose) of either IVIG or matching placebo given 24–36 hours apart, in addition to standard treatment.</p>
<p><strong>Main outcome measure</strong> The primary outcome was a ‘good recovery’ at 12 months after randomisation, defined as a score of≤2 on the Paediatric Glasgow Outcome Score Extended.</p>
<p><strong>Secondary outcome measures</strong> The secondary outcomes were clinical, neurological, neuroimaging and neuropsychological results, identification of the proportion of children with immune-mediated encephalitis, and IVIG safety data.</p>
<p><strong>Results</strong> 18 participants were recruited from 12 hospitals and randomised to receive either IVIG (n=10) or placebo (n=8) between 23 December 2015 and 26 September 2017. The study was terminated early following withdrawal of funding due to slower than anticipated recruitment, and therefore did not reach the predetermined sample size required to achieve the primary study objective; thus, the results are descriptive. At 12 months after randomisation, 9 of the 18 participants (IVIG n=5/10 (50%), placebo n=4/8 (50%)) made a good recovery and 5 participants (IVIG n=3/10 (30%), placebo n=2/8 (25%)) made a poor recovery. Three participants (IVIG n=1/10 (10%), placebo n=2/8 (25%)) had a new diagnosis of epilepsy during the study period. Two participants were found to have specific autoantibodies associated with autoimmune encephalitis. No serious adverse events were reported in participants receiving IVIG.</p>
<p><strong>Conclusions</strong> The IgNiTE (ImmunoglobuliN in the Treatment of Encephalitis) study findings support existing evidence of poor neurological outcomes in children with encephalitis. However, the study was halted prematurely and was therefore underpowered to evaluate the effect of early IVIG treatment compared with placebo in childhood encephalitis.</p>
<p><strong>Trial registration number</strong> Clinical Trials.gov NCT02308982; ICRCTN registry ISRCTN15791925.</p> |
| first_indexed | 2024-03-07T08:13:23Z |
| format | Journal article |
| id | oxford-uuid:ef267b4b-52c2-4467-a501-374a4b89e341 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:13:23Z |
| publishDate | 2023 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:ef267b4b-52c2-4467-a501-374a4b89e3412023-12-05T09:56:25ZIntravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ef267b4b-52c2-4467-a501-374a4b89e341EnglishSymplectic ElementsBMJ Publishing Group2023Hill, MIro, MSadarangani, MAbsoud, MCantrell, LChong, KClark, CEaston, AGray, VKneen, RLim, MLiu, XPike, MSolomon, TVincent, AWillis, LYu, L-MPollard, AJIgNiTE study team<p><strong>Objective</strong> To investigate whether intravenous immunoglobulin (IVIG) improves neurological outcomes in children with encephalitis when administered early in the illness.</p> <p><strong>Design</strong> Phase 3b multicentre, double-blind, randomised placebo-controlled trial.</p> <p><strong>Setting</strong> Twenty-one hospitals in the UK.</p> <p><strong>Participants</strong> Children aged 6 months to 16 years with a diagnosis of acute or subacute encephalitis, with a planned sample size of 308.</p> <p><strong>Intervention</strong> Two doses (1 g/kg/dose) of either IVIG or matching placebo given 24–36 hours apart, in addition to standard treatment.</p> <p><strong>Main outcome measure</strong> The primary outcome was a ‘good recovery’ at 12 months after randomisation, defined as a score of≤2 on the Paediatric Glasgow Outcome Score Extended.</p> <p><strong>Secondary outcome measures</strong> The secondary outcomes were clinical, neurological, neuroimaging and neuropsychological results, identification of the proportion of children with immune-mediated encephalitis, and IVIG safety data.</p> <p><strong>Results</strong> 18 participants were recruited from 12 hospitals and randomised to receive either IVIG (n=10) or placebo (n=8) between 23 December 2015 and 26 September 2017. The study was terminated early following withdrawal of funding due to slower than anticipated recruitment, and therefore did not reach the predetermined sample size required to achieve the primary study objective; thus, the results are descriptive. At 12 months after randomisation, 9 of the 18 participants (IVIG n=5/10 (50%), placebo n=4/8 (50%)) made a good recovery and 5 participants (IVIG n=3/10 (30%), placebo n=2/8 (25%)) made a poor recovery. Three participants (IVIG n=1/10 (10%), placebo n=2/8 (25%)) had a new diagnosis of epilepsy during the study period. Two participants were found to have specific autoantibodies associated with autoimmune encephalitis. No serious adverse events were reported in participants receiving IVIG.</p> <p><strong>Conclusions</strong> The IgNiTE (ImmunoglobuliN in the Treatment of Encephalitis) study findings support existing evidence of poor neurological outcomes in children with encephalitis. However, the study was halted prematurely and was therefore underpowered to evaluate the effect of early IVIG treatment compared with placebo in childhood encephalitis.</p> <p><strong>Trial registration number</strong> Clinical Trials.gov NCT02308982; ICRCTN registry ISRCTN15791925.</p> |
| spellingShingle | Hill, M Iro, M Sadarangani, M Absoud, M Cantrell, L Chong, K Clark, C Easton, A Gray, V Kneen, R Lim, M Liu, X Pike, M Solomon, T Vincent, A Willis, L Yu, L-M Pollard, AJ Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial |
| title | Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial |
| title_full | Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial |
| title_fullStr | Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial |
| title_full_unstemmed | Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial |
| title_short | Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial |
| title_sort | intravenous immunoglobulin treatment in childhood encephalitis ignite a randomised controlled trial |
| work_keys_str_mv | AT hillm intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT irom intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT sadaranganim intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT absoudm intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT cantrelll intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT chongk intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT clarkc intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT eastona intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT grayv intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT kneenr intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT limm intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT liux intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT pikem intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT solomont intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT vincenta intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT willisl intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT yulm intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial AT pollardaj intravenousimmunoglobulintreatmentinchildhoodencephalitisignitearandomisedcontrolledtrial |